Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Relevance

Click to order products descending

Display 15 Products per page

Ibrance
Read More
Ibrance (palbociclib; Pfizer) is a small-molecule inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6). When associated with cyclin-D proteins, CDK4/6 are able to phosphorylate and inactivate.
February 4, 2016
Find out more
Faslodex
Read More
Faslodex (fulvestrant; AstraZeneca) is an analog of 17 beta-estradiol, the dominant circulating estrogen, which competitively inhibits the binding of natural estradiol to the estrogen receptor (ER).
February 2, 2016
Find out more
MF-59 adjuvanted QIV
Read More
CSL’s MF-59 adjuvanted QIV is a subunit, surface antigen-containing seasonal QIV adjuvanted withMF59. It contains antigens from two A strains and two B strains specified by the World HealthOrganization seasonally for seasonal influenza vaccination.
February 2, 2016
Find out more
VLP QIV
Read More
Novavax’s virus-like particle (VLP) quadrivalent influenza vaccine (QIV), currently in Phase II

development, has the potential for significant market success if it is able to demonstrate superior

safety or efficacy data in Phase III studies.
February 2, 2016
Find out more
Ampyra
Read More
Ampyra is a potassium channel blocker, marketed by Acorda Therapeutics and Biogen, which is

approved to improve walking ability in multiple sclerosis patients. Although Ampyra’s active molecule

fampridine (4-aminopyridine) is readily available, by using Elan’s Intestinal Protective Drug Absorption

System, Acorda has developed a sustained-released oral tablet formulation allowing twice-daily

dosing.
January 26, 2016
Find out more
Zaltrap
Read More
Zaltrap is a human recombinant fusion protein comprising segments of the human VEGFRs 1 and 2
and the Fc portion of the human immunoglobulin G1 (Tang et al., 2008).
January 19, 2016
Find out more
Peretinoin
Read More
Peretinoin (Kowa/Chugai Pharmaceutical) is a synthetic acyclic retinoid inhibitor of transforming growth factor alpha (TGF-alpha) and platelet-derived growth factor receptor (PDGFR). TGF-alpha induces epithelial development, and is closely involved in hepatocarcinogenesis.
December 31, 2015
Find out more
Tivantinib
Read More
Tivantinib (ArQule/Daiichi Sankyo/Kyowa Hakko Kirin) is an orally available small molecule inhibitor of the hepatocyte growth factor (HGF) receptor, c-MET.
December 31, 2015
Find out more
F/TAF
Read More
F/TAF (emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a fixed-dose combination of two of Gilead’s nucleoside reverse transcriptase inhibitors, Emtriva (emtricitabine) and GS-7340 (TAF).
December 11, 2015
Find out more
D/C/F/TAF
Read More
D/C/F/TAF is a once-daily single-tablet regimen (STR) combination of the protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson), the two nucleoside reverse transcriptase inhibitors…
December 11, 2015
Find out more
Tybost
Read More
Tybost (cobicistat; Gilead) is a boosting agent to be used in combination with protease inhibitors (PIs) as part of treatment regimens for HIV-1 infection.
December 11, 2015
Find out more
Recentin
Read More
Recentin (cediranib; AstraZeneca) is a small molecule inhibitor of all three vascular endothelial growth factor receptor (VEGFR-1, -2, -3) tyrosine kinases.
October 30, 2015
Find out more
Vigil
Read More
Vigil (Gradalis) is an autologous tumor-based vaccine incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a novel.
October 30, 2015
Find out more
ChimeriVax-Dengue
Read More
ChimeriVax-Dengue (Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric LAVs.
October 28, 2015
Find out more
ProstAtak
Read More
ProstAtak (AdV-tk + valacyclovir) is a viral cancer vaccine being developed by Advantagene for the treatment of prostate cancer. It works by gene-mediated cytotoxic immunotherapy, an approach that generates a tumor-specific vaccine.
September 24, 2015
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *